Virus therapy for advanced bone and soft tissue tumors
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests an investigational virus therapy (R130) injected directly into tumors for people with advanced bone or soft tissue cancer who have exhausted standard treatments or choose not to pursue them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 16 and 75 years old with a confirmed diagnosis of soft tissue sarcoma or bone tumor.
- Standard cancer treatments must have stopped working, or you must choose not to receive other therapies.
- You need to have at least one tumor that can be safely injected with the study virus.
- Your overall health should be fairly good, as measured by an ECOG score of 0, 1, or 2.
- Your blood and organ function must meet specific lab requirements (like adequate blood counts and kidney/liver function).
- You cannot have active serious infections, uncontrolled heart conditions, or severe immune system problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests an injection of a virus designed to attack cancer cells in people with advanced solid tumors. It is meant for situations where standard treatments have not worked (or you can’t/won’t take them) and when doctors can directly deliver the treatment to a tumor spot.
This trial tests a new virus-based therapy (VG161) injected directly into tumors for people with advanced bone and soft tissue sarcoma that hasn't responded to other treatments. The goal is to see if the virus can shrink tumors and slow the cancer's growth.
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
This Phase 1 study tests STI-1386, an oncolytic (tumor-fighting) virus, for solid tumors that have relapsed or do not respond to treatment. It mainly checks safety, and also looks for early signs of how well it may work.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This study tests a personalized vaccine made from your tumor's unique mutations, combined with special immune cells grown from your blood, to treat advanced sarcoma (bone or soft tissue cancer) that did not respond to initial treatment. The goal is to help your immune system recognize and attack cancer cells.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.